| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Fmoc-Chg-OH targets peptide synthesis and drug design applications as a glycine derivative. The cyclohexylglycine residue can modulate peptide conformation and hydrophobicity. The Fmoc group enables standard Fmoc-based SPPS. It does not have a specific biological receptor target but is used in the synthesis of modified peptides.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity of Fmoc-Chg-OH is primarily as a peptide synthesis reagent. Amino acid derivatives have been used as ergogenic supplements, affecting the release of anabolic hormones and fuel availability. Fmoc-Chg-OH itself is not directly biologically active. Its utility is in preparing cyclohexylglycine-containing peptides for subsequent biological evaluation and drug design. |
| ln Vivo |
There is no specific in vivo activity data for Fmoc-Chg-OH as a standalone compound. Peptides containing cyclohexylglycine residues synthesized using this building block may be evaluated in vivo for therapeutic applications. The cyclohexyl group can enhance peptide stability and modulate target binding. Animal studies would be performed on the final peptide products.
|
| Enzyme Assay |
In vitro SPPS protocols for Fmoc-Chg-OH involve standard Fmoc chemistry. The compound is activated with coupling reagents such as HATU or HBTU (1 equiv) and DIPEA (2 equiv) in DMF, then coupled to resin-bound peptides. Fmoc deprotection uses 20% piperidine in DMF. Purity is ≥95% by HPLC. Coupling efficiency is monitored by HPLC or Kaiser test. Solubility in DMSO is 90 mg/mL.
|
| Cell Assay |
Cell-based protocols are not directly applicable to Fmoc-Chg-OH as it is a synthesis building block. Cyclohexylglycine-containing peptides synthesized using this reagent can be tested in cell culture. Peptides are dissolved in DMSO or appropriate buffers, sterile-filtered, and added to cells at concentrations of 0.1-100 µM. Incubation is typically 24-72 hours. Assays include cell viability, proliferation, and specific signaling readouts.
|
| Animal Protocol |
Animal studies with Fmoc-Chg-OH are not conducted directly. Peptides containing cyclohexylglycine residues synthesized using this building block may be evaluated in vivo. Protocols involve administration of the peptide via appropriate routes in animal models. Pharmacokinetic sampling, efficacy assessment, and toxicological evaluation follow standard preclinical study designs. The cyclohexyl group can influence peptide stability and bioavailability.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Fmoc-Chg-OH as a standalone compound is not applicable. The compound has molecular weight 379.45 g/mol, formula C₂₃H₂₅NO₄, and appears as a solid. Solubility in DMSO is 90 mg/mL. Storage: powder at -20°C. The Fmoc group is removed under basic conditions during peptide synthesis. The resulting cyclohexylglycine-containing peptides may have altered pharmacokinetics.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fmoc-Chg-OH is limited. The compound is for research use only. Standard safety precautions should be observed. Acute toxicity is expected to be low. Store as powder at -20°C. Proper personal protective equipment should be worn when handling. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Fmoc-Chg-OH (CAS#: 161321-36-4) is also known as Fmoc-L-cyclohexylglycine, N-Fmoc-2-cyclohexyl-L-glycine, and (2S)-2-cyclohexyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)acetic acid. Its molecular formula is C₂₃H₂₅NO₄ and molecular weight is 379.45 g/mol. It is a glycine derivative used in peptide synthesis and drug design. It has no approved therapeutic indications.
|
| Molecular Formula |
C23H25NO4
|
|---|---|
| Molecular Weight |
379.4489
|
| Exact Mass |
379.178
|
| CAS # |
161321-36-4
|
| PubChem CID |
6976353
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
602.9±38.0 °C at 760 mmHg
|
| Melting Point |
183 °C
|
| Flash Point |
318.4±26.8 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.601
|
| LogP |
5.6
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
28
|
| Complexity |
537
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CCC(CC1)[C@@H](C(=O)O)NC(=O)OCC2C3=CC=CC=C3C4=CC=CC=C24
|
| InChi Key |
BWQQGHPODCJZDB-NRFANRHFSA-N
|
| InChi Code |
InChI=1S/C23H25NO4/c25-22(26)21(15-8-2-1-3-9-15)24-23(27)28-14-20-18-12-6-4-10-16(18)17-11-5-7-13-19(17)20/h4-7,10-13,15,20-21H,1-3,8-9,14H2,(H,24,27)(H,25,26)/t21-/m0/s1
|
| Chemical Name |
(2S)-2-cyclohexyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)acetic acid
|
| Synonyms |
Cyclohexaneacetic acid, α-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, (S)-; Fmoc-Chg-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~263.54 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6354 mL | 13.1770 mL | 26.3539 mL | |
| 5 mM | 0.5271 mL | 2.6354 mL | 5.2708 mL | |
| 10 mM | 0.2635 mL | 1.3177 mL | 2.6354 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
